Hyperuricemia Treatment Market Size, Share, Opportunities, and Trends By Type of Disease (Gout, Chronic Kidney Diseases, Others), By Treatment Method (Uricosuric Agents, Xanthine Oxidase Inhibitors, Recombinant Uricases, Others), By End-User (Hospitals & Clinics, Specialty Diagnostic Centers, Others), And By Geography – Forecasts From 2025 To 2030

Hyperuricemia Treatment Market Size:

The Hyperuricemia Treatment Market is expected to grow at a CAGR of 6.31%, reaching a market size of US$4.329 billion in 2030 from US$3.188 billion in 2025

Hyperuricemia is a condition characterised by elevated levels of serum uric acid in the body, generally greater than 6 mg/dL in women and 7 mg/dL in men. It results from increased uric acid production, decreased excretion or a combination of both factors. This increase in the level of uric acid in the blood leads to disorders like gout, kidney stones, renal disorders, and chronic kidney diseases, and is linked to many other related diseases like cardiovascular diseases, diabetes, hypertension, fatty liver disease, Psoriasis, and some others. As per the data from the National Center for Biotechnology Information, up to 21% of the general population and 25% of hospitalized patients are estimated to have asymptomatic hyperuricemia.

Hyperuricemia Treatment Market Trends:

• Technological Advancements Propel Diagnosis and Treatment

Innovations in hyperuricemia management are accelerating market growth through enhanced diagnostics and therapies. Developments include advanced biomarker identification, genetic testing, and uricosuric drugs that reduce uric acid production. Novel drug delivery systems, such as nanoparticle-based targeted therapies, are also gaining traction. Research into precision treatments, like the combination of pegylated recombinant uricase (pegadricase) and immune tolerance technology for mTOR inhibitors (ImmTOR(TM)), is redefining gout therapy. Ongoing R&D efforts by institutions and universities continue to drive market expansion by offering innovative solutions for hyperuricemia and associated conditions.

Hyperuricemia Treatment Market Geographical Outlook:

• Asia Pacific to Experience Rapid Market Growth

The Asia Pacific region is projected to be the fastest-growing hyperuricemia market during the forecast period, driven by increasing prevalence due to sedentary lifestyles, obesity, diabetes, and hypertension. Countries like India (44.6% prevalence) and China (17.7% in 2017, per NHANES) are seeing rising cases. Improved healthcare access and growing awareness further contribute to market growth.

• North America Maintains Significant Market Share

North America holds a substantial share of the hyperuricemia market, supported by advanced healthcare infrastructure, an aging population, and sedentary lifestyles. The U.S. National Health and Nutrition Examination Survey estimates 21% of U.S. adults (43 million) and 20.6% of Mexicans have hyperuricemia. The National Institute of Diabetes and Digestive and Kidney Diseases reports that 11% of men and 6% of women experience kidney stones, with chronic kidney disease most prevalent among those aged 65+ (34%). These factors, combined with the aging demographic, drive market growth in the region.

Some of the major players covered in this report include Nippon Chemiphar, Astellas Pharma, AstraZeneca, Tonghua Dongbao Pharmaceutical, Teva Pharmaceutical Industries Ltd., Merck & Co., Sanofi SA, Pfizer Inc., among others.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Hyperuricemia Treatment Market Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions, including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments, among others)

The Hyperuricemia Treatment Market is analyzed into the following segments:

By Type of Disease

• Gout
• Chronic Kidney Diseases
• Others

By Treatment Method

• Uricosuric agents
• Xanthine Oxidase Inhibitors
• Recombinant Uricases
• Non-Pharmacological Interventions
• Others

By End-User

• Hospitals
• Clinics
• Others

By Geography

• North America
  • USA
  • Canada
  • Mexico
• South America
  • Brazil
  • Argentina
  • Others
• Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
• Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
• Asia Pacific
  • China
  • Japan
  • South Korea
  • Australia
  • India
  • Indonesia
  • Thailand
  • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. CXO Perspective

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View 

5. HYPERURICEMIA TREATMENT MARKET BY TYPE OF DISEASE

5.1. Introduction

5.2. Gout

5.3. Chronic Kidney Diseases

5.4. Others

6. HYPERURICEMIA TREATMENT MARKET BY TREATMENT METHOD

6.1. Introduction

6.2. Uricosuric agents

6.3. Xanthine Oxidase Inhibitors

6.4. Recombinant Uricases

6.5. Non-Pharmacological Interventions

6.6. Others

7. HYPERURICEMIA TREATMENT MARKET BY END-USER

7.1. Introduction

7.2. Hospitals

7.3. Clinics

7.4. Others  

8. HYPERURICEMIA TREATMENT MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Type of Disease

8.2.2. By Treatment Method

8.2.3. By End-User

8.2.4. By Country

8.2.4.1. USA

8.2.4.2. Canada

8.2.4.3. Mexico

8.3. South America

8.3.1. By Type of Disease

8.3.2. By Treatment Method

8.3.3. By End-User

8.3.4. By Country

8.3.4.1. Brazil

8.3.4.2. Argentina

8.3.4.3. Others

8.4. Europe

8.4.1. By Type of Disease

8.4.2. By Treatment Method

8.4.3. By End-User

8.4.4. By Country

8.4.4.1. United Kingdom

8.4.4.2. Germany

8.4.4.3. France

8.4.4.4. Spain

8.4.4.5. Others

8.5. Middle East and Africa

8.5.1. By Type of Disease

8.5.2. By Treatment Method

8.5.3. By End-User

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.2. UAE

8.5.4.3. Others

8.6. Asia Pacific

8.6.1. By Type of Disease

8.6.2. By Treatment Method

8.6.3. By End-User

8.6.4. By Country

8.6.4.1. China

8.6.4.2. Japan

8.6.4.3. South Korea

8.6.4.4. Australia

8.6.4.5. India

8.6.4.6. Indonesia

8.6.4.7. Thailand

8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Nippon Chemiphar

10.2. Astellas Pharma

10.3. AstraZeneca

10.4. Tonghua Dongbao Pharmaceutical

10.5. Teva Pharmaceutical Industries Ltd.

10.6. Merck & Co.

10.7. Sanofi SA

10.8. Pfizer Inc.

10.9. Amgen Inc.

10.10. Takeda Pharmaceutical Company Limited

10.11. Novartis AG

10.12. GlaxoSmithKline plc

10.13. Kissei Pharmaceutical Co., Ltd.

Nippon Chemiphar Co., Ltd.

Astellas Pharma Inc.

AstraZeneca plc

Tonghua Dongbao Pharmaceutical Co., Ltd.

Teva Pharmaceutical Industries Ltd.

Merck & Co., Inc.

Sanofi

Pfizer Inc.

Amgen Inc.

Takeda Pharmaceutical Company Limited

Novartis AG

GlaxoSmithKline plc

Kissei Pharmaceutical Co., Ltd.